JPMorgan added PTC Therapeutics (PTCT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $68 price target The selloff following the Complete Response Letter from the FDA for the Freidreich’s ataxia indication presents an attractive buying opportunity, the analyst tells investors in a research note. The firm is not surprised by the CRL and believes it is fully priced into the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target lowered to $76 from $82 at BofA
- PTC Therapeutics price target lowered to $73 from $79 at Wells Fargo
- PTC Therapeutics price target lowered to $63 from $64 at Jefferies
- RBC says PTC Therapeutics CRL may signal difficulty for Biohaven
- PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital